This post was originally published on this site

Korro Bio has got off a meaty series A funding round, nabbing $91.5 million to run its platform of single-base RNA edits to treat a range of diseases. The Cambridge, Massachusetts-based biotech will use the cash haul toward getting its preclinical program into the clinic, while also “establishing a broad portfolio of innovative RNA editingRead More »

The post Korro Bio hits the high notes with $91.5M series A to run its OPERA RNA platform appeared first on Atlas Venture.